在为乳腺癌治疗的患者中长期的局部区域复发
Beatriz Costeira1,2, Francisca Brito da Silva3, Filipa Fonseca3
1Breast Clinic, Instituto Português de Oncologia de Lisboa Francisco Gentil, Clínica da Mama, Rua Professor Lima Basto, 1099-023, Lisbon, Portugal. beatrizacosteira@gmail.com.
Breast cancer research and treatment
|September 14, 2023
概括
乳腺癌的局部区域复发 (LRR) 在7.6%的患者中发生,即使在16年后. 识别转移性淋巴结和瘤等级等危险因素对于个性化后续策略至关重要.
科学领域:
- 在瘤学瘤学.
- 乳腺癌研究研究 乳腺癌研究
- 手术瘤学手术瘤学
背景情况:
- 地方区域控制对于乳腺癌治疗和生存至关重要.
- 虽然大多数地方区域复发 (LRR) 发生在5年内,但晚期复发存在不明确的风险因素和生存影响.
- 了解长期LRR模式对于优化患者管理至关重要.
研究的目的:
- 评估长期乳腺癌队列中LRR的发生率和时间.
- 确定与LRR相关的预测因素.
- 评估LRR在最初的5年后对生存的影响.
主要方法:
- 在2002年至2004年期间接受治疗的1001名原发性乳腺癌患者的回顾性队列研究.
- 主要的终点:LRR. 二级终点:总体生存率 (OS),无疾病生存率 (DFS) 和LRR预测指标.
- 平均随访时间为197个月.
主要成果:
- 在197个月的中位数随访期间,观察到的全球LRR率为7.6%.
- 转移的状淋巴结和高组织学等级是LRR的显著预测因素 (p <0.05).
- 雌激素阴性瘤在前5年显示较高的LRR,但随着随访时间的延长,这种差异减少了. LRR与下降的OS相关 (p < 0.05).
结论:
- 在7.6%的患者中发生了LRR,在16年以后观察到复发.
- LRR与整体存活率降低有关.
- 瘤生物学影响LRR时间,这表明有必要制定量身定制的后续策略.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...